23 recruiting, 13 active not recruiting, 13 completed, 3 terminated. 23 Phase 2, 19 Phase 1, 7 Not applicable, 7 Phase 3, 2 Early Phase 1.
Follow Fludeoxyglucose (18f): new trials by email Literature Review of Fludeoxyglucose (18f) trials Research Report on Fludeoxyglucose (18f)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography - Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2025-06-17 | 2026-10-22 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer Abemaciclib, Anastrozole, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 60 | 2024-07-22 | 2026-09-24 |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-03-28 | 2024-05-01 | |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-01-23 | 2026-10-14 |
| Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging - Glioma | Completed | OHSU Knight Cancer Institute | 4 | 2023-12-11 | 2026-06-05 | |
| Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) - Multiple Myeloma, Plasma Cell Myeloma | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 20 | 2023-06-16 | 2026-09-16 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-29 |
Showing 20 of 54. Sign in to see all of them.
Breast Neoplasms (6) · Lung Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Oropharyngeal Neoplasms (4) · Anus Neoplasms (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Multiple Myeloma (3) · Neoplasm Metastasis (3) · Uterine Cervical Neoplasms (3) · Brain Neoplasms (2) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Glioblastoma (2)
National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (8) · City of Hope Medical Center (4) · Children's Oncology Group (3) · ECOG-ACRIN Cancer Research Group (3) · Jonsson Comprehensive Cancer Center (3) · University of Washington (3) · Stanford University (2) · Anusha Kalbasi (1) · Avid Radiopharmaceuticals (1) · Barbara Ann Karmanos Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (53) · Canada (7) · Puerto Rico (4) · Australia (2) · Ireland (1) · United Kingdom (1)
Christina Poh (2) · Dawid Schellingerhout (2) · Allison Betof Warner, MD, PhD (1) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · Antoni Ribas, MD, PhD (1) · Behnam Badie (1) · Behrang Amini (1) · Bhuvana A Setty (1) · Bill Loo (1) · Brittani K Seynnaeve (1) · Douglas W Sborov (1) · Dr Andrew Quon (1) · Eric D Miller (1) · Evan Osmundson, MD, PhD (1)
PMID 27256597, PMID 31174236, PMID 33843815, PMID 35787017, PMID 36269154, PMID 37505794, PMID 38107263, PMID 38947228, PMID 39208372, PMID 39365957, PMID 39673591, PMID 41047708, PMID 42497367, PMID 42702214
U10CA180820 (5), P30CA033572 (4), U10CA180886 (4), U10CA180821 (3), U10CA180868 (3), UM1CA186691 (2), P30CA016056 (1), P30CA016672 (1), P30CA022453 (1), P30CA068485 (1), P30CA138292 (1), R01CA249329 (1), R01CA271606 (1), R01CA279984 (1), R21CA137649 (1)